Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01667029 · ClinicalTrials.gov registry record · Phase 2
Study of Sulfasalazine in Treating Painful Neuropathy
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01667029: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01667029 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01667029, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The investigators hypothesize that sulfasalazine, an FDA-approved medication for rheumatoid arthritis and ulcerative colitis, may be beneficial in neuropathic pain conditions. In this study, the investigators will evaluate whether sulfasalazine improves pain due to painful peripheral neuropathy.
Primary Outcome
Average pain score will be the average of daily pain scores (0-10) recorded by the subject in a pain diary during the second week of the two week treatment period. Higher scores are worse (0=no pain, 10=pain as bad as you can imagine).
Interventions
- DRUG placebo
- DRUG Sulfasalazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-05 |
| Est. Completion | 2017-08-10 |
| Phase | Phase 2 |
Why NCT01667029 stopped before completion
NCT01667029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01667029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01667029 about?
NCT01667029 is a clinical study titled "Study of Sulfasalazine in Treating Painful Neuropathy". The investigators hypothesize that sulfasalazine, an FDA-approved medication for rheumatoid arthritis and ulcerative colitis, may be beneficial in neuropathic pain conditions. In this study, the investigators will evaluate whether sulfasalazine improves pain due to painful peripheral neuropathy.
What is the current status of trial NCT01667029?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-05. Estimated completion is 2017-08-10.
What interventions are being tested in trial NCT01667029?
The interventions under investigation include: placebo (DRUG), Sulfasalazine (DRUG).
Who is sponsoring clinical trial NCT01667029?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01667029's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia